ZDi Solutions, LLC Receives FDA Approval for Patented Proton Therapy & Conventional Radiation Therapy Positioning Devices

Wednesday, November 16, 2016 Medical Gadgets
Email Print This Page Comment bookmark
Font : A-A+

KNOXVILLE, Tenn., Nov. 16, 2016 /PRNewswire/ -- ZDi Solutions, LLC announced today that it has received approval from

the U.S. Food and Drug Administration for its Z-System™ patient positioning devices for proton therapy and conventional radiation therapy. The company announced in late September that it has begun marketing both in the U.S. and internationally. The
system is comprised of the Z-Box™, Z-Square™ and Z-Tilt™.

Photo - http://photos.prnewswire.com/prnh/20161115/439822

Photo - http://photos.prnewswire.com/prnh/20161115/439824

Said John Hawkins, CEO, "FDA approval was the next step in our launch process, and we are now very excited to introduce this product to the radiation oncology community with full credentials."

The devices, developed by Zachary Dutton, R.T. (R)(T), Chief Design Officer of ZDi Solutions, LLC, recognized and filled the need for proton-specific, patient-receptive positioning treatment aides. Dutton stated, "I am very pleased to have passed the rigorous FDA process.  I believe this further proves the safety, design, and quality of the ZDi, Solutions LLC devices."

The Z-System provides an innovative and revolutionary patient positioning unit to the Proton Therapy and conventional Radiation Therapy markets.  The unique, add-on line of patient centered products allows for greater efficiency and accuracy in simulation and treatment set- ups, thus allowing for increased quality and decreased liability.  The Z-System is the first of its kind to specifically target the needs and circumstances of proton therapy staffs and patients, while demonstrating to be beneficial for conventional Radiation Therapy treatments.  The initial products of the line aim to allow for best practices in patient positioning of the breast and thoracic areas; follow-up devices will focus on other anatomical regions and will operate cooperatively within the system.

ZDi Solutions, LLC has successfully tested and researched the device at the Provision Center for Proton Therapy in Knoxville, TN.

Cheryl Turner, Ed.D., R.T. (R)(T), ZDi's Chief Learning Officer, said, "The interest shown by national and international radiation oncology communities is a testament to our commitment in delivering highest quality products and service.  ZDi Solutions, LLC strives to excel in product research and development, consumer education, and stakeholder satisfaction.  We are pleased to meet this expectation in our drive towards future goals."

Hawkins added, "In addition to collaborative opportunities with U.S. radiation oncology providers, there has been significant international distribution interest from new and existing proton centers in Asia and India.  These are exciting markets that we are hopeful to explore."

ABOUT ZDI SOLUTIONS, LLCHeadquartered in Knoxville, TN, ZDi Solutions, LLC is an innovative patient positioning and immobilization device manufacturer in the radiation oncology market. The company has developed a line of unique patient-centered products that allow the radiation therapist/proton therapist to more efficiently and precisely prepare patients for different modalities of imaging and treatment. The Z-System™ devices increase the accuracy and constancy of the patient's position for reduced risk to the patient during treatments. They also decrease liability for facilities, while providing better patient outcomes. More information may be found at http://www.zdirad.com.

Agency:Chuck Morris Morris Creative Group LLC865-637-9869133675@email4pr.com

Company:John Hawkins, CEO, ZDi Solutions, LLC133675@email4pr.comwww.zdirad.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/zdi-solutions-llc-receives-fda-approval-for-patented-proton-therapy--conventional-radiation-therapy-positioning-devices-300363822.html

SOURCE ZDi Solutions, LLC

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store